🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

La disponibilité des ARV à bas coûts fait reculer le VIH/sida scidev.net/afrique-sub-sa… #Afrique #santé #SCiDEV #arv #Traitement #science #vih #developpememt #recherche

Great opportunity for diagnostic manufacturers

🗞️#PressRelease | 🎉The Medicines Patent Pool Unveils New Version🚀 of #MedsPaL 💻for Streamlined Access to #GlobalHealth #IntellectualProperty Information. Access our PR 👉🏾bit.ly/3UNSpqO 🔎#MedsPaL is a free resource that provides crucial information on the

Attending #WHA77❓ Make sure you register to the following MPP events (in-person 🤝 or/and online 💻 ) 👇 1️⃣/4 Cinema Premiere 🎞 on "The dolutegravir story: A Decade of Access" co-hosted with Unitaid. ⏰ 🗓 Tuesday 28 May, 18h30-20h, in-person 🤝 (followed by a reception). 📍

Noncommunicable diseases like heart disease, cancers, diabetes, chronic respiratory disease were the biggest killers, accounting for 3/4 of all deaths. During the #COVID19 pandemic, these diseases caused 78% of non-COVID deaths. 📊  bit.ly/4aEB74e

Looking forward to working closely with Indonesia to facilitate access to health products!

A Shot In The Arm Podcast Matthew Kavanagh [email protected] UNAIDS Global Kementerian Kesehatan RI Meg Doherty World Health Organization (WHO) Unitaid 🎤Esteban Burrone of MPP closes the session by highlighting 3️⃣ key moments of the #dolutegravir story: ✅ the signing of the licence with ViiV Healthcare in 2014. ✅ when TLD was approved in August 2017. This new fixed-dose combination regimen was created by generic manufacturers

Very disappointed to have missed the #G20 Health Working Group meeting this week. I tested positive for COVID at the airport as I was about to go through security. A reminder that COVID-19 is far from over....

When I started working in HIV, MSF International’s Untangling the Web was the first publication I was told to read to understand some of the access challenges being faced in LMICs. The breadth of expertise in the AC team has always been impressive. I’m concerned to hear latest developments…

Register and join GNP+ and PATA on 4 July for the #BetterMeds4Kids Children’s Access to Life-saving HIV Treatment webinar! Learn about the new #pALD dispersible tablet, a game-changer in children's HIV treatment. GAP-f Date: Thursday, 4 July, 2024 Time:

Following the MPP-ViiV agreement on #dolutegravir in late 2020, we're pleased to announce progress in the fight against #HIV in Azerbaijan🇦🇿, Belarus🇧🇾, Kazakhstan🇰🇿 & Malaysia🇲🇾👇 ✅ In Belarus & Kazakhstan, the volumes of DTG procured by national HIV programmes can cover 78%

#Publication📰 | Our latest article "Intellectual Property Licensing of Therapeutics During the #COVID19 Crisis: Lessons Learnt for #PandemicPreparedness and Response" published in Globalization and Health is out! This paper highlights the role of voluntary licensing in facilitating access to

Early engagement between MedicinesPatentPool and innovators, sometimes even before regulatory approval, helps fast-track generic development. This approach has been effective for HIV and COVID treatments, ensuring generics are ready as guidelines evolve, said Esteban Burrone at #AIDS2024.

At #AIDS2024, Esteban Burrone (Esteban Burrone) from the MedicinesPatentPool highlights that DTG-based regimens are now more affordable at $40 per patient per year, benefiting 24 million people globally and contributing to reduced carbon emissions.

Unitaid World Health Organization (WHO) Kenly Sikwese AFROCAB-HIV| Afrocab Treatment Access Partnership Francois Venter Wits University kenly sikwese ITPC Global Zack Panos CHAI GAP-f Helen McDowell Aurobindo Pharma Limited - Official 🎙️Esteban Burrone of MPP concludes the MPP/Unitaid session at #AIDS2024 by highlighting 3️⃣important lessons we can learn from the DTG story 👇🏼 ✅we need to have a parallel approach, and not do things sequentially; ✅in doing so, we need to be ready to take risks; ✅we need to be

AMPROU Anne-Claire Unitaid ANRS Maladies infectieuses émergentes Expertise France IRD.fr France Diplomatie 🇫🇷🇪🇺 Bokk Yakaar 🎙️Esteban Burrone du MPP explique que le MPP contribue à la réponse contre l’épidémie du VIH/sida en accélérant l’accès aux médicaments essentiels dans les pays à revenu faible et intermédiaire en négociant des licences volontaires avec les laboratoires innovants ce qui permet ensuite

Esteban Burrone (Esteban Burrone) du MedicinesPatentPool rappelle que malgré les progrès réalisés, comme le dolutégravir coûtant aussi peu que 40 $ par an, il reste encore beaucoup à faire pour garantir un accès universel aux médicaments contre le VIH. #AIDS2024

AMPROU Anne-Claire Unitaid ANRS Maladies infectieuses émergentes Expertise France IRD.fr France Diplomatie 🇫🇷🇪🇺 Bokk Yakaar Esteban Burrone 🎙️Esteban Burrone du MPP au stand de la 🇫🇷 Le programme de transfert de technologies à ARNm a été créé par World Health Organization (WHO) et le MPP avec le soutien de la #France 🇫🇷 et d’autres pays suite à l’épidémie de #COVID19 afin d’améliorer la santé et la sécurité sanitaire en développant pour le long

"Tools on their own don't end epidemics," says Esteban Burrone from the MedicinesPatentPool at #AIDS2024. Long-acting PrEP could significantly reduce the 1.3 million new HIV infections yearly, but we need millions on PrEP.

📢 Exciting News in Cancer Treatment Access! The Medicines Patent Pool (MPP), ATOM Coalition, IDA Foundation, and The Max Foundation are thrilled to announce that MPP sublicensee Hetero has received FDA approval for its generic version of nilotinib, a vital medication for #CML.